ARTICLE | Clinical News

FDA lifts hold on Cel-Sci's Ph III trial of Multikine in SCCHN

October 27, 2017 6:53 PM UTC

Cel-Sci Corp. (NYSE-M:CVM) said FDA lifted a clinical hold on the Phase III IT-MATTERS trial of Multikine leukocyte interleukin injection to treat squamous cell carcinoma of the head and neck (SCCHN).

The open-label, international trial had enrolled 928 patients before FDA placed the hold last September after it identifiing issues in trial documents related to investigator conduct and reporting (see BioCentury, Oct. 3, 2016 & June 23, 2017)...

BCIQ Company Profiles

Cel-Sci Corp.

Ergomed plc